What is the 13F Pro Quality Score for LGND?

13F Pro ranks LIGAND PHARMACEUTICALS INC (LGND) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LGND's current score at https://13fpro.ai/research/LGND (free sign-up required for the full ranking).

Where does 13F Pro source LGND data?

All LIGAND PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. LIGAND PHARMACEUTICALS INC files with the SEC under CIK 886163. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LGND in?

LIGAND PHARMACEUTICALS INC (LGND) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LGND research updated on 13F Pro?

LGND's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LIGAND PHARMACEUTICALS INC(LGND)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 886163 LGND stock profile & AI dashboard →

13F Pro Quality Score

66.0/100

Rank #547 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.2/100

Profitability

90.3/100

Balance Sheet

66.1/100

Earnings Quality

14.8/100

Free Cash Flow

77.9/100

Institutional Flow

59.0/100

Revenue Scale

27.5/100

Dilution Risk

10.7/100

LGND Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LIGAND PHARMACEUTICALS INC (LGND), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LGND at 66.0/100 on a 32-signal composite quality model, placing it at rank #547 of 2,879 stocks — the top 25% of the AI-ranked universe. LGND scores in the top quartile across profitability (90.3), revenue growth (90.2), free cash flow (77.9). Areas of concern include earnings quality (14.8) and revenue scale (27.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), LIGAND PHARMACEUTICALS INC reports quarterly revenue of $51.7M, net income of $-13.3M, free cash flow of $48.5M. Top institutional holders of LGND by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, JANUS HENDERSON GROUP PLC, based on the most recent SEC filings. LGND trades on the Nasdaq exchange and files with the SEC under CIK 886163. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LGND daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LIGAND PHARMACEUTICALS INC directly from SEC EDGAR. LIGAND PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 8 and 76 since 2021, currently 66.0 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about LIGAND PHARMACEUTICALS INC

Quirks, history, and lore behind LGND — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap pharmaceutical company headquartered in San Diego · listed on Nasdaq · operates in the healthcare sector with a very unusual business model.
2
The Numbers
Revenue is in the low hundreds of millions annually, yet its profit margins are the envy of Big Pharma — because it barely spends money making drugs itself.
3
The History
Founded in the early 1990s, it spent years as a traditional biotech before pivoting to become essentially a royalty collector for the pharmaceutical industry.
4
The Secret
Its actual product is intellectual property — it licenses drug technologies, collects royalties on other companies' sales, and lets everyone else do the hard manufacturing work.
5
The Lore
Its Captisol drug-formulation technology appears in a surprisingly large number of FDA-approved medicines, making it a quiet toll booth on the pharmaceutical highway.
6
The Giveaway
Think of it as the royalty streaming company of pharma — its portfolio includes stakes tied to Kyprolis, Teriparatide, and dozens more, all without running a single clinical trial itself.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$51.7M

Net Income

Q1 2026

$-13.3M

Free Cash Flow

Q1 2026

$48.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+60.4% YoY

$268.1MFY 2025

FY22 $196.2MFY23 $131.3MFY24 $167.1MFY25 $268.1M

Net Income

+3186.6% YoY

$124.5MFY 2025

FY22 $-33.4MFY23 $52.2MFY24 $-4.0MFY25 $124.5M

Operating Income

+281.4% YoY

$41.0MFY 2025

FY22 $3.0MFY23 $11.9MFY24 $-22.6MFY25 $41.0M

EPS (Diluted)

+2886.4% YoY

$6.13FY 2025

FY22 $-1.98FY23 $2.94FY24 $-0.22FY25 $6.13

Total Assets

+65.7% YoY

$1.56BFY 2025

FY22 $762.7MFY23 $787.2MFY24 $941.8MFY25 $1.56B

Op. Cash Flow

-49.1% YoY

$49.4MFY 2025

FY22 $137.8MFY23 $49.6MFY24 $97.0MFY25 $49.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$268.1M +60.4%	$167.1M +27.3%	$131.3M -33.1%	$196.2M +20.0%	$163.6M +36.0%	$120.3M
Net Income	$124.5M +3186.6%	$-4.0M -107.7%	$52.2M +256.3%	$-33.4M -1017.6%	$-3.0M -100.5%	$629.3M
Operating Income	$41.0M +281.4%	$-22.6M -289.3%	$11.9M +293.2%	$3.0M -91.9%	$37.5M -95.4%	$807.1M
EPS (Diluted)	$6.13 +2886.4%	$-0.22 -107.5%	$2.94 +248.5%	$-1.98 -1000.0%	$-0.18 -100.6%	$31.85
Total Assets	$1.56B +65.7%	$941.8M +19.6%	$787.2M +3.2%	$762.7M -44.0%	$1.36B -8.9%	$1.49B
Operating Cash Flow	$49.4M -49.1%	$97.0M +95.8%	$49.6M -64.0%	$137.8M +152.5%	$54.6M +286.1%	$-29.3M

Get alerted when LGND's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LIGAND PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LGND

BlackRock, Inc.
$591.3M2,961,923 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$219.7M1,100,267 sh
JANUS HENDERSON GROUP PLC
$201.6M1,009,891 sh
VANGUARD CAPITAL MANAGEMENT LLC
$169.3M848,089 sh
Invesco Ltd.
$164.4M823,604 sh
STATE STREET CORP
$155.5M778,856 sh
FMR LLC
$119.0M596,127 sh
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$114.5M573,312 sh
FRANKLIN RESOURCES INC
$114.4M573,177 sh
Chicago Capital, LLC
$112.1M561,675 sh

Fund	Value	Shares
BlackRock, Inc.	$591.3M	2,961,923
VANGUARD PORTFOLIO MANAGEMENT LLC	$219.7M	1,100,267
JANUS HENDERSON GROUP PLC	$201.6M	1,009,891
VANGUARD CAPITAL MANAGEMENT LLC	$169.3M	848,089
Invesco Ltd.	$164.4M	823,604
STATE STREET CORP	$155.5M	778,856
FMR LLC	$119.0M	596,127
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	$114.5M	573,312
FRANKLIN RESOURCES INC	$114.4M	573,177
Chicago Capital, LLC	$112.1M	561,675

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LGND on your watchlist

Track score changes the day LIGAND PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LGND a good stock to buy?

13F Pro's AI-powered analysis of LIGAND PHARMACEUTICALS INC (LGND) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LGND are available on the LGND stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LGND?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LGND. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LIGAND PHARMACEUTICALS INC's investment landscape.